Mitapivat for phosphofructokinase deficiency.
作者信息
Al-Samkari Hanny
机构信息
Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Am J Hematol. 2024 Oct;99(10):2045-2046. doi: 10.1002/ajh.27442. Epub 2024 Jul 23.
Abstract
摘要
相似文献
1
Mitapivat for phosphofructokinase deficiency.米他匹法特用于磷酸果糖激酶缺乏症。
Am J Hematol. 2024 Oct;99(10):2045-2046. doi: 10.1002/ajh.27442. Epub 2024 Jul 23.
2
Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.米他匹伐：一种用于治疗丙酮酸激酶缺乏症成人溶血性贫血的喹诺酮磺酰胺类药物。
Am J Ther. 2023;30(5):e433-e438. doi: 10.1097/MJT.0000000000001663.
3
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.米他培坦：成人丙酮酸激酶缺乏症的治疗药物。
Drugs. 2023 Nov;83(17):1613-1620. doi: 10.1007/s40265-023-01961-x. Epub 2023 Nov 22.
4
Mitapivat versus Placebo for Pyruvate Kinase Deficiency.米替培南侧重于安慰剂用于治疗丙酮酸激酶缺乏症。
N Engl J Med. 2022 Apr 14;386(15):1432-1442. doi: 10.1056/NEJMoa2116634.
5
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.米拉帕维特治疗接受常规输血的丙酮酸激酶缺乏症成年患者（ACTIVATE-T）：一项多中心、开放标签、单臂、3 期临床试验。
Lancet Haematol. 2022 Oct;9(10):e724-e732. doi: 10.1016/S2352-3026(22)00214-9. Epub 2022 Aug 18.
6
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.米他膦酸酯可改善丙酮酸激酶缺乏症成年患者无效红细胞生成和铁过载。
Blood Adv. 2024 May 28;8(10):2433-2441. doi: 10.1182/bloodadvances.2023011743.
7
How We Treat Hemolytic Anemia Due to Pyruvate Kinase Deficiency.我们如何治疗丙酮酸激酶缺乏所致的溶血性贫血。
Hematol Rep. 2024 Aug 31;16(3):559-567. doi: 10.3390/hematolrep16030054.
8
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.米他匹伐，一种新型丙酮酸激酶激活剂，用于治疗遗传性溶血性贫血。
Ther Adv Hematol. 2021 Dec 21;12:20406207211066070. doi: 10.1177/20406207211066070. eCollection 2021.
9
Relative Bioavailability Studies With Mitapivat: Formulation and Food Effect Assessments in Healthy Subjects.米他匹韦的相对生物利用度研究：健康受试者的制剂和食物效应评估
Clin Pharmacol Drug Dev. 2024 Dec;13(12):1271-1282. doi: 10.1002/cpdd.1481. Epub 2024 Oct 25.
10
Mitapivat for sickle cell disease and thalassemia.米替膦酸治疗镰状细胞病和地中海贫血。
Drugs Today (Barc). 2023 Mar;59(3):125-134. doi: 10.1358/dot.2023.59.3.3521880.
本文引用的文献
1
Mitapivat versus Placebo for Pyruvate Kinase Deficiency.米替培南侧重于安慰剂用于治疗丙酮酸激酶缺乏症。
N Engl J Med. 2022 Apr 14;386(15):1432-1442. doi: 10.1056/NEJMoa2116634.
2
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.米他匹伐，一种新型丙酮酸激酶激活剂，用于治疗遗传性溶血性贫血。
Ther Adv Hematol. 2021 Dec 21;12:20406207211066070. doi: 10.1177/20406207211066070. eCollection 2021.
3
Phosphofructokinase deficiency; past, present and future.磷酸果糖激酶缺乏症：过去、现在与未来
Curr Mol Med. 2002 Mar;2(2):197-212. doi: 10.2174/1566524024605734.
4
The RAND 36-Item Health Survey 1.0.兰德36项健康调查1.0版。
Health Econ. 1993 Oct;2(3):217-27. doi: 10.1002/hec.4730020305.
Zotero 插件